NCT06427941 2026-03-18
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
9 trialsNCT06715839 2025-12-31
Target-specific immunoPET Imaging of Digestive System Carcinoma
RenJi Hospital
Phase NA Recruiting
NCT06478693 2025-12-18
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Myeloid Therapeutics
Phase 1 Recruiting
NCT05263830 2025-12-16
IMMUNOGLYPIC
Assistance Publique - Hôpitaux de Paris
Recruiting
NCT06687941 2025-03-21
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Aptamer Sciences, Inc.
Phase 1 Recruiting
NCT03198546 2024-06-25
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Second Affiliated Hospital of Guangzhou Medical University
Phase 1 Recruiting
NCT04728139 2022-01-13
Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients
Assiut University
Phase NA Unknown
NCT04121273 2021-03-03
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1 Unknown
NCT02723942 2020-07-16
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn